Madrigal Pharmaceuticals, Inc.

Pagina dedicata companiei Madrigal Pharmaceuticals, Inc. listata cu simbolul US.MDGL

Descriere companieModificare

Madrigal Pharmaceuticals, Inc. (http://www.madrigalpharma.com) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

Grafic actiuni companieModificare

Ultimele stiri despre Madrigal Pharmaceuticals, Inc. (US.MDGL)Modificare